E-ISSN 2149-388X | ISSN 2149-0430
 
2025, Vol: 11, Issue: 1
11 / 1Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded

Cover Letter
License Agreement
Title Page

Case Report 


A Case of Scleredema Diabeticorum: Could Pentoxifylline Be a Therapeutic Option?

Habibullah Aktas, Serkan Oner, Zulal Oner.


Abstract
Background: Scleredema diabeticorum is a dermatosis characterized by hardening of skin over the upper back. It is commonly seen in poor-controlled diabetic patients. Therapeutic options are limited. Psoralen and ultraviolet A therapy (PUVA), methotrexate, and topical steroids have been used with some success. Pentoxifylline is a xanthine derivative used mainly in peripheral vascular diseases. It also has antifibrotic effects due to its collagen synthesis inhibition action.
Case Presentation: In this paper, a trial of intralesional pentoxifylline treatment and magnetic resonance images of a male patient with scleredema diabeticorum are presented. Some subjective symptoms of the patient improved after this treatment, but, the thickness of the lesion did not change.
Conclusion: Pentoxifylline, probably via the oral route, could still be thought in such patients unresponsive to conventional approaches due to its antifibrotic activity and high safety profile.

Key words: Scleredema, Pentoxifylline, MRI


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Habibullah Aktas
Articles by Serkan Oner
Articles by Zulal Oner
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Aktas H, Oner S, Oner Z. A Case of Scleredema Diabeticorum: Could Pentoxifylline Be a Therapeutic Option?. Ulutas Med J. 2019; 5(3): 225-228. doi:10.5455/umj.20190616024428

Web Style

Aktas H, Oner S, Oner Z. A Case of Scleredema Diabeticorum: Could Pentoxifylline Be a Therapeutic Option?. https://www.ulutasmedicaljournal.com/?mno=53006 [Access: March 15, 2025]. doi:10.5455/umj.20190616024428

AMA (American Medical Association) Style

Aktas H, Oner S, Oner Z. A Case of Scleredema Diabeticorum: Could Pentoxifylline Be a Therapeutic Option?. Ulutas Med J. 2019; 5(3): 225-228. doi:10.5455/umj.20190616024428


Vancouver/ICMJE Style

Aktas H, Oner S, Oner Z. A Case of Scleredema Diabeticorum: Could Pentoxifylline Be a Therapeutic Option?. Ulutas Med J. (2019), [cited March 15, 2025]; 5(3): 225-228. doi:10.5455/umj.20190616024428


Harvard Style

Aktas, H., Oner, . S. & Oner, . Z. (2019) A Case of Scleredema Diabeticorum: Could Pentoxifylline Be a Therapeutic Option?. Ulutas Med J, 5 (3), 225-228. doi:10.5455/umj.20190616024428


Turabian Style

Aktas, Habibullah, Serkan Oner, and Zulal Oner. 2019. A Case of Scleredema Diabeticorum: Could Pentoxifylline Be a Therapeutic Option?. THE ULUTAS MEDICAL JOURNAL, 5 (3), 225-228. doi:10.5455/umj.20190616024428


Chicago Style

Aktas, Habibullah, Serkan Oner, and Zulal Oner. "A Case of Scleredema Diabeticorum: Could Pentoxifylline Be a Therapeutic Option?." THE ULUTAS MEDICAL JOURNAL 5 (2019), 225-228. doi:10.5455/umj.20190616024428


MLA (The Modern Language Association) Style

Aktas, Habibullah, Serkan Oner, and Zulal Oner. "A Case of Scleredema Diabeticorum: Could Pentoxifylline Be a Therapeutic Option?." THE ULUTAS MEDICAL JOURNAL 5.3 (2019), 225-228. Print. doi:10.5455/umj.20190616024428


APA (American Psychological Association) Style

Aktas, H., Oner, . S. & Oner, . Z. (2019) A Case of Scleredema Diabeticorum: Could Pentoxifylline Be a Therapeutic Option?. THE ULUTAS MEDICAL JOURNAL, 5 (3), 225-228. doi:10.5455/umj.20190616024428


Author LoginReviewer LoginAbout PublisherOpen Access PolicyEditorial PoliciesEditorial Review PolicyPeer Review PolicyEditorial & Peer Review ProcessAuthor's Rights and ObligationsPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Privacy PolicyCorrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesDigital Archiving & Preservation PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information

About THE ULUTAS MEDICAL JOURNAL

The Ulutas Medical Journal (UMJ) is a 3 monthly (quarterly), open access, double-blind peer-reviewed, an international journal. Writing a research pap ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information


Journal Owner
HAYRİYE ZEHRA ULUTAŞ
Phone: +90 (532) 165 96 39​
E-mail: zehrakenanoglu@hotmail.com​
Address: Alaattin Mah. 30. Ada sok. D11 Blok
No:4 Gungor Uydukent Sitesi  Antakya/HATAY

Editor-In-Chief
KEMAL TURKER ULUTAS, MD, Assc. Prof.
Phone: + 90 (555) 491 35 59​
E-mail: drkemalturker@gmail.com
Address: Alaattin Mah. 30. Ada sok. D11 Blok
No:4 Gungor Uydukent Sitesi  Antakya/HATAY

Publisher Information
SCOPEMED Publishing Co. - TURKEY​
E-mail: scopemed@scopemed.org
Web: https://www.scopemed.com/

 

We welcome your submissions, suggestions, comments, or questions. To reach us, please use one of the methods provided on this page or Email us at ulutasmedicaljournal@gmail.com​

We will respond within 48 to 72 hours.